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dEffect of Blood Hematocrit and Erythrocyte Deformability on
Adenosine 5=-Diphosphate Platelet Reactivity in Patients With
Acute Coronary Syndromes on Dual Antiplatelet Therapy
Emanuele Cecchi, MDa,b, Rossella Marcucci, MDa, Rita Paniccia, BSca, Brunella Bandinelli, BSca,
Serafina Valente, MDa, Cristina Giglioli, MDa, Chiara Lazzeri, MDa, Gian Franco Gensini, MDa,b,
Rosanna Abbate, MDa, and Lucia Mannini, MDa,*
Previous studies have explored the association between hemorheologic alterations and
aspirin resistance, pointing out the possible interaction between hematologic components
and platelet responsiveness to antiplatelet drugs. The aim of this study was to evaluate the
association between hemorheologic variables and residual platelet reactivity in patients
with acute coronary syndromes (ACSs) who underwent percutaneous coronary interven-
tion on dual antiplatelet therapy. The study population included 528 patients with ACSs.
Hemorheologic studies were performed by assessing whole blood viscosity at 0.512 and 94.5/
second, plasma viscosity, and erythrocyte deformability index. Post-treatment platelet reactiv-
ity was investigated by measuring platelet aggregation by adenosine 5=-diphosphate (ADP) 10
mol and a value >70% was defined as high ADP platelet reactivity. Significantly (p <0.01)
lower values of hematocrit and erythrocyte deformability and higher values of whole blood
viscosity at 94.5/second were found in patients with high ADP platelet reactivity. At multivar-
iate analysis, lower values of hematocrit and erythrocyte deformability index and higher values
of whole blood viscosity at 94.5/second and leukocytes (highest vs lowest tertile) also resulted in
an independent association with high platelet reactivity, except for leukocytes, after simulta-
neous adjustment for hematocrit, leukocyte count, and erythrocyte deformability index. In
conclusion, these results demonstrate the influence of hematocrit and of erythrocyte deform-
ability on ADP platelet reactivity. These variables could be considered to optimize treatment
with antiplatelet therapy in these patients. © 2009 Elsevier Inc. All rights reserved. (Am J
Cardiol 2009;104:764–768)
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mUse of clopidogrel in addition to acetylsalicylic acid has
een demonstrated to be associated with a decrease of
ardiovascular events in patients with acute coronary syn-
romes (ACSs) independently of stent implantation.1,2 Ret-
ospective studies have shown that discontinuation of clo-
idogrel, even 6 months after stent implantation, is
ssociated with an increased risk of thrombotic events in
atients with drug-eluting stents.3,4 However, interindi-
idual variabilities in response to clopidogrel and acetylsal-
cylic acid have been reported in patients with ACS.5 From
hese assumptions, the phenomenon of clopidogrel resis-
ance has progressively gained great interest6,7 and recent
tudies have shown that decreased responsiveness to clopi-
ogrel is associated with an increased incidence of death
nd cardiovascular events8 and is a strong predictor of stent
hrombosis after drug-eluting stent implantation.9 Previous
tudies have reported an association between hemorheo-
aDipartimento di Area Critica Medico-Chirurgica, Centro Trombosi,
zienda Ospedaliero-Universitaria Careggi, and bFondazione Don Carlo
nocchi Onlus, Centro IRCCS “Santa Maria agli Ulivi”, Impruneta, Flo-
ence, Italy. Manucript received January 27, 2009; revised manuscript
eceived and accepted May 2, 2009.
This work was supported by grants from Ente Cassa di Risparmio di
irenze to the Fiorgen Foundation, Florence, Italy.
*Corresponding author: Tel: 39-055-7949582; fax: 39-055-7949418.
TE-mail address: manninil@aou-careggi.toscana.it (L. Mannini).
002-9149/09/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
oi:10.1016/j.amjcard.2009.05.005ogic variables and aspirin resistance.10,11 The aim of this
tudy was to evaluate the possible association between he-
orheologic variables and residual platelet reactivity to
denosine 5=-diphosphate (ADP) in patients with ACS on
ual antiplatelet therapy.
ethods
The study population included 528 consecutive patients
ith a diagnosis of ACS, 272 with ST-segment elevation
yocardial infarction (STEMI), and 256 with non-STEMI
r unstable angina pectoris (UAP) admitted from March
004 to December 2006 to the intensive and postintensive
oronary care units of the department of medical and sur-
ical critical area of the Azienda Ospedaliero-Universitaria
areggi (Florence, Italy) after undergoing percutaneous
oronary intervention (PCI).
Acute MI was diagnosed from an increase in creatine
inase-MB isoenzyme 2 times the upper limit (3.6 ng/ml)
nd/or increased cardiac troponin I (0.15 ng/ml) levels
ith 1 of the following: acute onset of prolonged (20
inutes) typical chest pain, ST-segment elevation of 1
m in 2 contiguous electrocardiographic leads, or new
eft bundle branch block on 12-lead electrocardiogram for a
iagnosis of STEMI, and ST-segment depression of 0.5
m 0.08 second after the J point in 2 contiguous leads or
-wave inversion 1 mm in leads with predominant R
www.AJConline.org
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765Coronary Artery Disease/Hemorheologic Variables and High ADP Platelet Reactivityaves for the diagnosis of non-STEMI. STEMI was diag-
osed in 272 patients and non-STEMI in 92. UAP was
efined according to Braunwald classification and only pa-
ients with class IIIb UAP were enrolled. All patients un-
erwent coronary angiography performed by the Judkins
echnique and PCI; coronary vessels were defined as dis-
ased when stenosis 70% was detected.
Traditional cardiovascular risk factors, assessed by pa-
ient interviews, echocardiography, and hospital records,
ere defined as presented in Table 1. Bleeding complica-
ions, major and minor, were defined according to Voeltz et
l.12 Exclusion criteria for patients with STEMI were a total
able 1
linical characteristics of subjects investigated
ariable Low
Reactivity
High
Reactivity
p
Value
(n  427) (n  101)
ge (years), median (range) 68 (28–92) 73 (22–94) 0.001
en/women 266/161 63/38 1.0
ypertension* 250 (58.5%) 64 (63.4%) 0.4
yslipidemia† 173 (40.5%) 40 (39.6%) 0.9
moker 185 (43.3%) 43 (42.6%) 0.9
iabetes mellitus‡ 86 (20.1%) 26 (25.7%) 0.2
besity§ 83 (19.4%) 22 (21.8%) 0.6
amily history of coronary
artery disease
136 (31.9%) 42 (41.6%) 0.08
istory of coronary artery
disease¶
162 (37.9%) 44 (43.6%) 0.3
revious PCI 95 (22.2%) 23 (22.8%) 0.9
revious coronary artery bypass
grafting
27 (6.3%) 4 (4.0%) 0.5
TEMI 216 (50.6%) 56 (55.4%) 0.4
on-STEMI 76 (17.8%) 16 (15.8%) 0.8
AP 135 (31.6%) 29 (28.7%) 0.6
ultivessel disease 300 (70.3%) 63 (62.4%) 0.2
ulprit coronary artery
Left main 20 (4.7%) 5 (5.0%) 1.0
Left anterior descending 203 (47.5%) 50 (49.5%) 0.7
Right 123 (28.8%) 32 (31.7%) 0.6
Left circumflex 75 (17.6%) 14 (13.9%) 0.5
Others 9 (2.1%) 0 (0.0%) 0.2
enal dysfunction# 26 (6.1%) 8 (7.9%) 0.5
leeding complications 38 (0.09%) 12 (0.12%) 0.3
ngiotensin-converting enzyme
inhibitors
387 (90.6%) 90 (89.1%) 0.7
blockers 367 (85.9%) 77 (76.2%) 0.02
tatins 385 (90.2%) 86 (85.1%) 0.2
iuretics 236 (55.3%) 55 (54.5%) 0.9
itrates 257 (60.2%) 68 (67.3%) 0.2
lycoproteins IIb/IIIa inhibitors 221 (51.8%) 36 (35.6%) 0.004
* Defined as the presence of blood pressure values 140/90 mm Hg
ccording to guidelines of the European Society of Hypertension/European
ociety of Cardiology and/or antihypertensive treatment.
† Defined according to the Third Report of the National Cholesterol
ducation Program.
‡ Defined according to the American Diabetes Association.
§ Defined as a body mass index 30 kg/m2.
 Defined as the presence of 1 first-degree relative who had developed
oronary artery disease before age 55 years for men and 65 years for
omen.
¶ Defined as a history of MI or stable and unstable angina.
# Defined as a creatinine clearance 60 ml/min/m2.atency period 12 hours and creatinine serum levels 4 rg/dl. Patients’ demographic and clinical data were col-
ected. All subjects gave their informed consent and the
nvestigation was approved by the institutional committee
n human research.
Blood samples for hemorheologic parameters and plate-
et reactivity assessment were collected simultaneously in
he morning 6 hours after PCI but 48 hours after the
ccurrence of symptoms. A clopidogrel 600-mg loading
ose was administered to each patient before PCI. For
atients receiving in the catheter laboratory the loading dose
f clopidogrel and a glycoprotein IIb/IIIa inhibitor, blood
amples were obtained after 48 hours while the patient
as on clopidogrel 75-mg maintenance dose. Hemorheo-
ogic studies were performed by assessing whole blood
iscosity, plasma viscosity, and erythrocyte deformability
ndex as previously reported.13 Whole blood viscosity and
lasma viscosity were measured at 37°C using the Rota-
ional Viscosimeter LS 30 (Contraves, Zurich, Switzerland).
hole blood viscosity was analyzed at shear rates of 0.512
nd 94.5/second. Plasma viscosity testing was performed at
hear rate of 94.5/second. Erythrocyte filtration was mea-
ured by a microcomputer-assisted filtrometer (model MF4,
yrenne GmbH, Roetgen, Germany). For platelet reactivity
ssessment blood samples were obtained after clopidogrel
oading and were anticoagulated with sodium citrate 0.129
ol/L (ratio 9:1). Platelet-rich plasma, obtained by centri-
uging whole blood for 10 minutes at 200g, was stimulated
ith ADP 10 mol/L (Mascia Brunelli, Milan, Italy) and
esidual aggregation was assessed using a APACT 4 light
ransmittance aggregometer (Helena Laboratories, Milan,
taly). The 100% line was set using platelet-poor plasma and
baseline established with platelet-rich plasma (adjusted
rom 18 up to 30  109/L). Platelet aggregation (according
o the Born method) was evaluated by considering maximal
ercent platelet aggregation in response to a stimulus. Ac-
ording to data from the literature and our group,8,9 patients
ith platelet aggregation by ADP 10 mol 70% (90th
ercentile of controls) were considered as having high ADP
latelet reactivity. For the different hemorheologic proce-
ures, intra-assay coefficients of variation were 1.6% and
nterassay coefficients of variation were 4.5%. Fibrinogen
as measured by clotting assay; intra- and interassay coef-
cients of variation were 2.2% and 3.8%, respectively.
ean coefficient of variation for ADP-induced platelet ag-
regation was 6.8%.
Statistical analysis was performed using SPSS 11.5 for
indows (SPSS, Inc., Chicago, Illinois). Data are given as
edian and range. To investigate the association between
linical and hemorheologic variables and residual platelet
eactivity, patients with ACS were divided in 2 groups
ccording to the presence of high residual platelet reactivity
n dual antiplatelet therapy. Categorical variables were
ompared using chi-square test. Mann-Whitney test was
erformed to evaluate differences in hemorheologic vari-
bles in relation to the presence of high ADP platelet reac-
ivity. Correlations between hemorheologic variables and
latelet aggregation measured with ADP 10 mol were
erformed by Pearson test.
Multinomial regression analyses were performed to eval-
ate the independent association between high ADP platelet
eactivity and hemorheologic variables using residual plate-
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766 The American Journal of Cardiology (www.AJConline.org)et reactivity as a dependent variable. Variables generally
ccepted as influencing high ADP platelet reactivity were
ncluded in the analysis (age, gender, hypertension, dys-
ipidemia, smoking habits, diabetes mellitus, obesity, re-
al dysfunction, bleeding complications, pharmacologic
herapy, family and personal histories of coronary artery
isease) in a model (model 1) in which each hemorheo-
ogic variable was added separately. Another model in
hich results of hemorheologic variables, independently
ssociated to high ADP platelet reactivity in model 1
nalysis, were adjusted for white blood cell count, he-
atocrit, and erythrocyte deformability index was also
erformed (model 2).
All regression coefficients are given with 95% confi-
ence intervals. A p value 0.05 was considered statisti-
ally significant.
esults
Clinical characteristics of patients are listed in Table 1.
are metal stents were implanted in 147 of 449 patients
igure 1. Multivariate logistic regression analysis for high (70%) ADP pla
ge, arterial hypertension, smoking habit, dyslipidemia, diabetes mellitus, o
leeding complications, and pharmacologic therapy. ‡Adjusted also for leuk
R  odds ratio.
able 2
emorheologic parameters in relation to high adenosine 5=-diphosphate p
ariable Low Rea
(n  4
ematocrit (%) 37.9 (24.7–
hole blood viscosity at 0.512/s (mPa/s) 24.16 (18.16
hole blood viscosity at 94.5/s (mPa/s) 4.38 (3.80–
lasma viscosity (mPa/s) 1.48 (1.25–
rythrocyte deformability index 5.35 (1.56–
ibrinogen (mg/dl) 452 (223–
eukocytes  109/L 8,290 (4,190
latelets  109/L 195 (100–ith ACS and drug-eluting stents in 302 of 449. One hun- sred one of 528 patients with ACS showed persistently high
DP platelet reactivity on dual antiplatelet therapy admin-
stration.
Significantly lower values of hematocrit and erythrocyte
eformability index and slightly higher values of whole
lood viscosity at 94.5/second were found in relation to high
esidual platelet reactivity (Table 2). No significant differ-
nce was found between patients with high ADP platelet
eactivity and those without in relation to type of stent
mplanted (bare metal or drug eluting). No significant dif-
erence in platelet count was found between patients with
ematocrit values below the first tertile and the others.
Mild, but significant, correlations between platelet ag-
regation by ADP 10 mol and hematocrit (r  0.26, p 
.000), erythrocyte deformability index (r0.36, p 0.000),
hole blood viscosity at 94.5/second (r  0.17, p  0.000),
lasma viscosity (r  0.16, p  0.000), and fibrinogen (r 
.15, p  0.000) were observed.
At multinomial regression analyses hematocrit, erythro-
yte deformability index, whole blood viscosity at 94.5/
ctivity in patients with ACSs. *p0.05; **p0.01. †Adjusted for gender,
family and personal histories of coronary artery disease, renal dysfunction,
ount, hematocrit, and erythrocyte deformability. CI  confidence interval;
eactivity
High Reactivity p Value
(n  101)
36.4 (23.7–44.8) 0.002
) 24.93 (19.15–38.71) 0.6
4.40 (3.80–5.81) 0.001
1.50 (1.28–2.21) 0.1
2.00 (1.50–12.00) 0.000
469 (158–890) 0.3
0) 9,140 (4,110–24,160) 0.2
191 (101–617) 0.6telet rea
besity,
ocyte clatelet r
ctivity
27)
54.9)
–45.21
6.71)
2.20)
13.68)
1,720)
–22,59econd, and leukocytes in the highest versus lowest tertile
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767Coronary Artery Disease/Hemorheologic Variables and High ADP Platelet Reactivitynd age, family history of coronary artery disease, and more
imited use of glycoprotein IIb/IIIa inhibitors and  blockers
esulted in an independent association with high ADP plate-
et reactivity in model 1 analysis (Figure 1). In model 2
nalysis erythrocyte deformability index, hematocrit, and
hole blood viscosity at 94.5/second in the highest versus
owest tertile remained independently associated with high
DP platelet reactivity (Figure 1).
iscussion
Previous studies have shown a significant association
etween a decreased responsiveness to clopidogrel and an
ncreased rate of thrombotic events8,9 and possible alterna-
ive therapeutic strategies have been suggested. In fact, it
as been proposed to double the mean daily dosage of
lopidogrel, which has been demonstrated to determine a
ore intense inhibition of platelet aggregation than the
urrently recommended 75-mg maintenance dose14 or to
dminister a different antiplatelet drug such as ticlopidine or
rasugrel, a third-generation thienopyridine that has been
ecently demonstrated to provide greater and faster P2Y(12)
eceptor-mediated platelet inhibition than clopidogrel.15
Moreover, a high clopidogrel loading dose in patients
ndergoing coronary stenting has been shown to optimize
latelet inhibitory effects soon after intervention, possibly
roviding a more effective protection against early throm-
otic complications.16
A possible role of hemorheologic variables in influenc-
ng aspirin resistance has been recently described,10,11 con-
rming the role of erythrocytes and leukocytes in the patho-
enesis of arterial thrombosis.
The novel finding of the present study is the significant
ssociation between some hemorheologic variables and
igh residual ADP platelet reactivity in patients with ACS
n dual antiplatelet therapy. In particular, we found an
ndependent association between decreased erythrocyte de-
ormability and increased platelet aggregation induced by
DP. A possible explanation for this relation is that eryth-
ocytes with decreased deformability tend to release a larger
mount of ADP in the circulation compared to those with-
ut17 and ADP released can compete against clopidogrel for
urinergic receptors present on the platelet surface, thus
xplaining the high ADP platelet reactivity in these patients.
Thus, another possible target to increase clopidogrel
esponsiveness should be administration of drugs capable
f improving erythrocyte deformability, among which one
hould consider administration of -3 fatty acids18; in fact,
sh oil administration has been previously reported to de-
ermine a decrease in ADP release from shear-stressed
rythrocytes by increasing their filterability.17 Moreover,
-3 fatty acids have been previously reported to determine
decrease in platelet aggregation,19 a mechanism that could
ontribute, at least in part, to longer survival.
Another interesting finding of the present study is the
ild but significant negative correlation between hematocrit
nd high ADP platelet reactivity. Because anemia has been
reviously reported to be associated with a higher rate of
eath and thrombotic events in patients with ACS,20 the
ecreased responsiveness to clopidogrel found in our study
n patients with ACS and lower hematocrit values could, at meast in part, account for the higher rate of thrombotic events
n these patients.
Moreover, this result agrees with those of a recent report
howing an independent association between lower hemat-
crit values and aspirin resistance in patients with stable
oronary artery disease.21
Decreased erythrocyte mass could be associated with a
ower availability of nitric oxide, which has been recently
emonstrated to be reversibly bound, transported, and re-
eased by erythrocytes in the cardiovascular system under
hysiologic and pathologic conditions.22 Erythrocytes ex-
ress an active and functional endothelium-type nitric oxide
ynthase, which is localized in the plasma membrane and
he cytoplasm of erythrocytes22; in human erythrocytes ni-
ric oxide regulates deformability of the erythrocyte mem-
rane and inhibits platelet function due to an increase of
ntracellular cyclic guanosine monophosphate levels in
latelets.23 Moreover, it has been demonstrated that eryth-
ocytes are capable of releasing adenosine triphosphate by
echanical deformation or pharmacologically, thus favor-
ng nitric oxide release by activated platelets.24
In contrast, anemic patients with ACSs, except those
ith very low hematocrit, do not seem to benefit from
dministration of blood transfusions that, on the contrary,
re associated with a worse outcome25; the negative impact
f blood transfusions in patients presenting with anemia and
uspected ACS has been confirmed and ascribed to the
hange in shape and deformability of stored erythrocytes,25
hich probably release a larger amount of ADP, thus further
ecreasing platelet responsiveness to antiplatelet drugs.
The association between anemia and higher values of
latelet aggregation found in our patients could be ex-
lained by the presence of a large number of reticulated
latelets.
Recently, a significant negative correlation has been re-
orted between hematocrit and reticulated platelet number,
hich in turn has been associated with persistent platelet
eactivity in patients on dual antiplatelet therapy.26 Reticu-
ated platelets are metabolically and enzymatically more
ctive than smaller platelets; their increased number in ane-
ic patients should be explained by a compensatory pro-
uction from stimulated bone marrow of larger reticulated
latelets.27
These patients, however, could benefit from administra-
ion of nitric oxide donors such as LA419, which has been
ecently reported to have antithrombotic properties.28
In the present study, leukocytes in the highest versus
owest tertile resulted in an independent association with
igh ADP residual platelet reactivity in model 1 analysis but
ot after adjustment for hematocrit levels and erythrocyte
eformability index values. This result suggests that alter-
tions of these latter variables play a pivotal role in influ-
ncing platelet responsiveness to antiplatelet drugs whose
echanism of action is mediated by ADP receptors.
A limitation of this study is that we did not provide the
umber of reticulocytes, which have been demonstrated to
e responsible for decreased erythrocyte deformability in
nemic patients with reticulocytosis.29 Reticulocytes have
ower deformability and lower membrane fluidity than ma-
ure red blood cells and these indexes normalize during
aturation.30 However, decreased erythrocyte deformabil-
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768 The American Journal of Cardiology (www.AJConline.org)ty and lower hematocrit values resulted in an independent
ssociation with high platelet reactivity, suggesting their
ndependent role in modulating responsiveness to antiplate-
et drugs.
Another limitation of the present study is that we did not
easure ADP plasma levels in the 2 groups of patients with
ecreased and normal erythrocyte deformabilities, so we
an only speculate that increased levels of ADP in patients
ith decreased erythrocyte deformability may explain the
ncreased ADP platelet reactivity.
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